BioCatalyst

INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5 — catalyst calendar

1 verified catalyst event(s) referencing INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-30
in 4mo
ESTIMATED
 READOUT
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) i
Phase 1/2 · Solid Tumor, Non-Small Cell Lung Cancer
 INBX Inhibrx Biosciences, Inc. INBRX-106 - Hexavalent OX40 agonist anti ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.